Sheetal Ankolekar, MD
Family Practice · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ankolekar’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A125643 · Current
Licensed to practise in California · since 2013 · expires 2027-03-31 · Kuvempu University, J.J.M. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$58,286
Medicare paid this office $58,286 for 490 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 233 | $23,486 | $84 |
| New patient visit (30+ min) | 148 | $13,500 | $91 |
| Return visit (30+ min) | 57 | $6,656 | $111 |
| New patient visit (45+ min) | 25 | $3,519 | $141 |
| Short return visit | 48 | $2,807 | $50 |
See all 12 services
| Short return visit (20+ min) | 233 | $23,486 | $84 |
| New patient visit (30+ min) | 148 | $13,500 | $91 |
| Return visit (30+ min) | 57 | $6,656 | $111 |
| New patient visit (45+ min) | 25 | $3,519 | $141 |
| Short return visit | 48 | $2,807 | $50 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 48 | $2,564 | $50 |
| New patient visit (15+ min) | 19 | $970 | $51 |
| Injection of drug or substance under skin or into muscle | 33 | $513 | $14 |
| Urinalysis, manual test | 74 | $297 | $3 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 12 | $194 | $16 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $23 | None |
| Injection, ketorolac tromethamine, per 15 mg | 15 | $16 | None |
Procedures Medicare counted
| Removal of tissue | 1-10 | None |
| Removal or shaving of skin growth | 1-10 | None |
Who their Medicare patients are
490 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 18% · Women 68% · Also on Medicaid 10% · Health risk score 1.08. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 73% · Diabetes 24% · Coronary heart disease 22% · Chronic kidney disease 20% · Atrial fibrillation 19% · Depression 18% · Cancer 16% · Heart failure 11% · COPD 10% · Stroke 8% · Dementia 7%.
The office billed $253,563, Medicare allowed $80,906 and paid $58,286; for 1,092 services of 51 kinds; $273 of it was for drugs given in the office and $58,013 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 490 | 1,092 | 76 | 1.08 | $253,563 | $58,286 |
| 2023 | 442 | 828 | 76 | 1.04 | $230,332 | $54,268 |
| 2022 | 404 | 800 | 76 | 1.09 | $217,316 | $50,787 |
| 2021 | 444 | 774 | 75 | 1.09 | $171,011 | $45,720 |
| 2020 | 302 | 616 | 75 | 1.13 | $143,773 | $32,932 |
| 2019 | 575 | 1,223 | 75 | 1.20 | $275,140 | $63,741 |
| 2018 | 441 | 934 | 75 | 1.20 | $237,199 | $55,178 |
| 2017 | 356 | 728 | 75 | 1.15 | $154,091 | $39,494 |
| 2016 | 454 | 1,030 | 74 | 1.17 | $225,765 | $59,654 |
| 2015 | 300 | 620 | 74 | 1.16 | $123,466 | $36,147 |
| 2014 | 286 | 528 | 74 | 1.30 | $86,855 | $27,287 |
| 2013 | 19 | 49 | 73 | 2.10 | $12,102 | $4,582 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Short return visit (20+ min) | 256 | $24,825 | $82 |
| Return visit (30+ min) | 74 | $9,149 | $119 |
| New patient visit (30+ min) | 82 | $7,027 | $86 |
| New patient visit (45+ min) | 18 | $2,727 | $152 |
| Short return visit | 41 | $2,565 | $53 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 40 | $2,061 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 21 | $302 | $14 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 18 | $292 | $15 |
| Urinalysis, manual test | 66 | $242 | $3 |
| Injection of drug or substance under skin or into muscle | 17 | $201 | $11 |
| Injection, ketorolac tromethamine, per 15 mg | 11 | $10 | None |
2022: 10 services
| Short return visit (20+ min) | 213 | $21,025 | $83 |
| Return visit (30+ min) | 99 | $12,085 | $115 |
| New patient visit (30+ min) | 45 | $3,542 | $79 |
| New patient visit (45+ min) | 19 | $3,027 | $159 |
| Short return visit | 45 | $2,403 | $43 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 45 | $2,281 | $51 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 24 | $409 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $322 | $27 |
| Urinalysis, manual test | 50 | $199 | $3 |
| Injection of drug or substance under skin or into muscle | 13 | $176 | $12 |
2021: 11 services
| Short return visit (20+ min) | 180 | $17,330 | $85 |
| Return visit (30+ min) | 59 | $7,088 | $118 |
| Short return visit | 75 | $4,901 | $53 |
| New patient visit (30+ min) | 38 | $3,902 | $103 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 110 | $3,748 | $30 |
| New patient visit (45+ min) | 15 | $2,481 | $165 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 11 | $564 | $51 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 12 | $198 | $17 |
| Urinalysis, manual test | 46 | $167 | $3 |
| Injection of drug or substance under skin or into muscle | 12 | $158 | $12 |
| Injection, ketorolac tromethamine, per 15 mg | 13 | $10 | None |
2020: 7 services
| Return visit (30+ min) | 147 | $14,069 | $89 |
| Short return visit (20+ min) | 92 | $6,010 | $56 |
| Long return visit (40+ min) | 34 | $4,243 | $125 |
| New patient visit (30+ min) | 17 | $1,337 | $79 |
| Injection of drug or substance under skin or into muscle | 16 | $268 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 14 | $202 | $13 |
| Urinalysis, manual test | 37 | $131 | $3 |
2019: 18 services
| Return visit (30+ min) | 310 | $30,569 | $87 |
| Short return visit (20+ min) | 224 | $16,418 | $63 |
| New patient visit (45+ min) | 28 | $3,487 | $125 |
| New patient visit (30+ min) | 34 | $2,894 | $85 |
| Long return visit (40+ min) | 17 | $2,111 | $117 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 48 | $678 | $13 |
| New patient visit (15+ min) | 12 | $665 | $55 |
| Detection test by immunoassay with direct visual observation for influenza virus | 21 | $649 | $16 |
| Injection of drug or substance under skin or into muscle | 25 | $465 | $16 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $396 | $36 |
| Inhalation treatment for airway obstruction or sputum production | 20 | $370 | $15 |
| Urinalysis, manual test | 64 | $276 | $3 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 13 | $211 | $16 |
| Removal of impacted ear wax by washing | 11 | $183 | $13 |
| Blood glucose (sugar) test performed by hand-held instrument | 17 | $64 | $3 |
| Infusion, normal saline solution , 1000 cc | 11 | $23 | None |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 14 | $2 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 19 | $1 | None |
2018: 14 services
| Return visit (30+ min) | 288 | $31,059 | $90 |
| Long return visit (40+ min) | 50 | $6,633 | $128 |
| New patient visit (45+ min) | 45 | $5,067 | $113 |
| Short return visit (20+ min) | 58 | $3,807 | $61 |
| New patient visit (30+ min) | 12 | $1,074 | $90 |
| Injection of drug or substance under skin or into muscle | 30 | $666 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 39 | $614 | $15 |
| Detection test by immunoassay with direct visual observation for influenza virus | 11 | $357 | $16 |
| Evaluation of use of breathing device | 18 | $319 | $18 |
| Inhalation treatment for airway obstruction or sputum production | 14 | $274 | $20 |
| Urinalysis, manual test | 32 | $109 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 12 | $42 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 15 | $17 | None |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 12 | $2 | None |
2017: 10 services
| Return visit (30+ min) | 247 | $23,610 | $83 |
| New patient visit (45+ min) | 33 | $4,166 | $126 |
| Short return visit (20+ min) | 48 | $2,888 | $56 |
| Long return visit (40+ min) | 19 | $2,755 | $125 |
| New patient visit (30+ min) | 18 | $1,049 | $58 |
| Injection of drug or substance under skin or into muscle | 18 | $535 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | $278 | $12 |
| Evaluation of use of breathing device | 13 | $242 | $17 |
| Inhalation treatment for airway obstruction or sputum production | 12 | $239 | $18 |
| Urinalysis, manual test | 22 | $79 | $3 |
2016: 17 services
| Return visit (30+ min) | 281 | $29,524 | $85 |
| New patient visit (45+ min) | 66 | $8,349 | $126 |
| Short return visit (20+ min) | 91 | $6,500 | $60 |
| Long return visit (40+ min) | 33 | $4,292 | $126 |
| New patient visit (30+ min) | 13 | $1,132 | $87 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $1,018 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 49 | $722 | $14 |
| Injection of drug or substance under skin or into muscle | 26 | $657 | $22 |
| Administration of vaccine | 13 | $268 | $21 |
| Inhalation treatment for airway obstruction or sputum production | 12 | $261 | $19 |
| Diphtheria and tetanus vaccine (7 years or older) | 11 | $191 | $17 |
| Blood glucose (sugar) test performed by hand-held instrument | 13 | $56 | $3 |
| Urinalysis, manual test | 14 | $51 | $3 |
| Infusion, normal saline solution , 1000 cc | 22 | $33 | None |
| Injection, ketorolac tromethamine, per 15 mg | 11 | $11 | None |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 11 | $2 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 13 | $1 | None |
2015: 11 services
| Return visit (30+ min) | 172 | $17,217 | $94 |
| New patient visit (45+ min) | 37 | $4,978 | $135 |
| Short return visit (20+ min) | 68 | $4,830 | $64 |
| Long return visit (40+ min) | 17 | $2,413 | $142 |
| New patient visit (30+ min) | 16 | $1,561 | $98 |
| Injection of drug or substance under skin or into muscle | 16 | $507 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 29 | $484 | $17 |
| Inhalation treatment for airway obstruction or sputum production | 11 | $224 | $20 |
| Urinalysis, manual test | 15 | $58 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 11 | $24 | None |
| Infusion, normal saline solution , 1000 cc | 11 | $16 | None |
2014: 8 services
| Short return visit (20+ min) | 184 | $12,315 | $61 |
| Return visit (30+ min) | 61 | $6,105 | $97 |
| New patient visit (30+ min) | 39 | $3,499 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 19 | $288 | $15 |
| Evaluation of use of breathing device | 12 | $214 | $18 |
| Inhalation treatment for airway obstruction or sputum production | 12 | $211 | $18 |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 13 | $2 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 13 | $1 | None |
2013: 1 service
| Return visit (30+ min) | 11 | $1,690 | $99 |
Drugs they prescribed that Part D paid
$12,171
Pharmacies billed $12,171 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (12 of 755) in 2024. At or below the middle of the specialty; the typical family practice clinician is at 2%.
669 generic and fewer than 11 brand-name prescriptions · $12,171 in drug cost · 301 antibiotic prescriptions to 264 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Paxlovid | 38 | $4,226 | $111 |
| Doxycycline Hyclate | 99 | $853 | $9 |
| Nitrofurantoin Mono-Macro | 53 | $737 | $14 |
| Diclofenac | 37 | $642 | $17 |
| Montelukast | 58 | $566 | $10 |
See all 18 drugs
| Paxlovid | 38 | $4,226 | $111 |
| Doxycycline Hyclate | 99 | $853 | $9 |
| Nitrofurantoin Mono-Macro | 53 | $737 | $14 |
| Diclofenac | 37 | $642 | $17 |
| Montelukast | 58 | $566 | $10 |
| Albuterol Sulfate Hfa | 18 | $430 | $24 |
| Amoxicillin-Clavulanate Potass | 54 | $425 | $8 |
| Benzonatate | 25 | $234 | $9 |
| Ibuprofen | 38 | $139 | $4 |
| Prednisone | 30 | $130 | $4 |
| Azithromycin | 36 | $114 | $3 |
| Omeprazole | 12 | $109 | $9 |
| Cephalexin | 19 | $104 | $5 |
| Gabapentin | 12 | $85 | $7 |
| Hydroxyzine | 15 | $69 | $5 |
| Ondansetron | 11 | $67 | $6 |
| Meloxicam | 12 | $59 | $5 |
| Tizanidine | 14 | $37 | $3 |
Year by year
| 2024 | 755 | 499 | 2% (12) | None | $12,171 |
| 2023 | 673 | 445 | 3% (23) | 6% | $12,352 |
| 2022 | 656 | 422 | 5% (30) | None | $14,159 |
| 2021 | 533 | 358 | 6% (34) | 6% | $8,291 |
| 2020 | 340 | 205 | 9% (29) | None | $9,138 |
| 2019 | 654 | 451 | 6% (40) | None | $16,643 |
| 2018 | 500 | 370 | 8% (38) | None | $11,168 |
| 2017 | 460 | 311 | 11% (49) | 12% | $7,319 |
| 2016 | 425 | 275 | 12% (52) | 12% | $8,850 |
| 2015 | 459 | 282 | 11% (52) | None | $9,985 |
| 2014 | 629 | 247 | 11% (67) | 17% | $19,791 |
| 2013 | 131 | 16 | None | None | $6,485 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Diclofenac | 60 | $1,542 | $26 |
| Doxycycline Hyclate | 67 | $1,232 | $18 |
| Amoxicillin-Clavulanate Potass | 51 | $683 | $13 |
| Nitrofurantoin Mono-Macro | 34 | $648 | $19 |
| Albuterol Sulfate Hfa | 19 | $518 | $27 |
| Omeprazole | 35 | $352 | $10 |
| Azithromycin | 50 | $329 | $7 |
| Benzonatate | 15 | $313 | $21 |
| Ondansetron | 12 | $221 | $18 |
| Cephalexin | 16 | $197 | $12 |
| Paxlovid (Eua) | 18 | $162 | $9 |
| Gabapentin | 13 | $146 | $11 |
| Hydroxyzine | 16 | $140 | $9 |
| Tizanidine | 14 | $101 | $7 |
| Sulfamethoxazole-Trimethoprim | 12 | $90 | $8 |
| Prednisone | 18 | $87 | $5 |
| Ibuprofen | 16 | $46 | $3 |
| Tramadol | 15 | $31 | $2 |
2022: 17 drugs
| Diclofenac | 83 | $2,170 | $26 |
| Nitrofurantoin Mono-Macro | 40 | $850 | $21 |
| Amoxicillin-Clavulanate Potass | 41 | $581 | $14 |
| Doxycycline Hyclate | 37 | $577 | $16 |
| Valacyclovir | 12 | $456 | $38 |
| Azithromycin | 40 | $229 | $6 |
| Omeprazole | 33 | $227 | $7 |
| Cephalexin | 23 | $218 | $9 |
| Ondansetron | 18 | $180 | $10 |
| Tizanidine | 14 | $167 | $12 |
| Ibuprofen | 27 | $138 | $5 |
| Sulfamethoxazole-Trimethoprim | 25 | $123 | $5 |
| Lidocaine Hcl Viscous | 12 | $99 | $8 |
| Hydroxyzine | 11 | $83 | $8 |
| Acetaminophen-Codeine | 12 | $78 | $7 |
| Prednisone | 14 | $56 | $4 |
| Tramadol | 13 | $39 | $3 |
2021: 15 drugs
| Diclofenac | 56 | $1,381 | $25 |
| Nitrofurantoin Mono-Macro | 34 | $775 | $23 |
| Doxycycline Hyclate | 21 | $523 | $25 |
| Valacyclovir | 12 | $393 | $33 |
| Cephalexin | 32 | $336 | $11 |
| Amoxicillin-Clavulanate Potass | 23 | $311 | $14 |
| Sulfamethoxazole-Trimethoprim | 38 | $234 | $6 |
| Tizanidine | 20 | $210 | $11 |
| Ibuprofen | 40 | $172 | $4 |
| Azithromycin | 17 | $169 | $10 |
| Ciprofloxacin | 17 | $125 | $7 |
| Losartan | 12 | $83 | $7 |
| Gabapentin | 11 | $61 | $6 |
| Prednisone | 11 | $61 | $6 |
| Tramadol | 23 | $55 | $2 |
2020: 8 drugs
| Diclofenac | 32 | $947 | $30 |
| Amoxicillin-Clavulanate Potass | 20 | $249 | $12 |
| Ibuprofen | 32 | $140 | $4 |
| Sulfamethoxazole-Trimethoprim | 21 | $118 | $6 |
| Ciprofloxacin | 15 | $105 | $7 |
| Azithromycin | 13 | $95 | $7 |
| Cephalexin | 14 | $92 | $7 |
| Tramadol | 21 | $60 | $3 |
2019: 14 drugs
| Diclofenac | 34 | $1,115 | $33 |
| Amoxicillin-Clavulanate Potass | 68 | $924 | $14 |
| Azithromycin | 85 | $778 | $9 |
| Doxycycline Hyclate | 23 | $613 | $27 |
| Nitrofurantoin Mono-Macro | 22 | $479 | $22 |
| Ondansetron Odt | 12 | $432 | $36 |
| Cephalexin | 35 | $365 | $10 |
| Ciprofloxacin | 32 | $363 | $11 |
| Ibuprofen | 36 | $203 | $6 |
| Sulfamethoxazole-Trimethoprim | 28 | $196 | $7 |
| Hydrocodone-Acetaminophen | 11 | $128 | $12 |
| Prednisone | 33 | $125 | $4 |
| Tramadol | 25 | $106 | $4 |
| Ibu | 11 | $42 | $4 |
2018: 12 drugs
| Amoxicillin-Clavulanate Potass | 67 | $889 | $13 |
| Proair Hfa | 13 | $789 | $61 |
| Azithromycin | 73 | $623 | $9 |
| Doxycycline Hyclate | 14 | $482 | $34 |
| Nitrofurantoin Mono-Macro | 12 | $329 | $27 |
| Ciprofloxacin | 25 | $254 | $10 |
| Ibuprofen | 32 | $164 | $5 |
| Cephalexin | 16 | $134 | $8 |
| Sulfamethoxazole-Trimethoprim | 22 | $105 | $5 |
| Tramadol | 22 | $82 | $4 |
| Prednisone | 19 | $81 | $4 |
| Ibu | 14 | $51 | $4 |
2017: 13 drugs
| Ventolin Hfa | 11 | $593 | $54 |
| Amoxicillin-Clavulanate Potass | 37 | $445 | $12 |
| Nitrofurantoin Mono-Macro | 19 | $377 | $20 |
| Azithromycin | 59 | $323 | $5 |
| Ciprofloxacin | 27 | $223 | $8 |
| Doxycycline Hyclate | 11 | $215 | $20 |
| Doxycycline Monohydrate | 11 | $162 | $15 |
| Ibuprofen | 29 | $113 | $4 |
| Cephalexin | 15 | $98 | $7 |
| Prednisone | 18 | $71 | $4 |
| Sulfamethoxazole-Trimethoprim | 15 | $61 | $4 |
| Hydrocodone-Acetaminophen | 12 | $56 | $5 |
| Tramadol | 26 | $50 | $2 |
2016: 12 drugs
| Proair Hfa | 18 | $980 | $54 |
| Nitrofurantoin Mono-Macro | 23 | $607 | $26 |
| Amoxicillin-Clavulanate Potass | 31 | $433 | $14 |
| Azithromycin | 42 | $332 | $8 |
| Ibuprofen | 42 | $263 | $6 |
| Omeprazole | 12 | $177 | $15 |
| Ciprofloxacin | 20 | $151 | $8 |
| Hydrocodone-Acetaminophen | 21 | $142 | $7 |
| Cephalexin | 14 | $126 | $9 |
| Sulfamethoxazole-Trimethoprim | 12 | $86 | $7 |
| Tramadol | 22 | $61 | $3 |
| Prednisone | 12 | $58 | $5 |
2015: 13 drugs
| Proair Hfa | 14 | $715 | $51 |
| Amoxicillin-Clavulanate Potass | 36 | $507 | $14 |
| Ibuprofen | 51 | $326 | $6 |
| Azithromycin | 29 | $227 | $8 |
| Nitrofurantoin Mono-Macro | 12 | $224 | $19 |
| Hydrocodone-Acetaminophen | 15 | $185 | $12 |
| Ciprofloxacin | 28 | $168 | $6 |
| Omeprazole | 15 | $142 | $9 |
| Tramadol | 34 | $138 | $4 |
| Cephalexin | 20 | $127 | $6 |
| Prednisone | 14 | $73 | $5 |
| Gabapentin | 11 | $72 | $7 |
| Sulfamethoxazole-Trimethoprim | 14 | $65 | $5 |
2014: 20 drugs
| Lantus | 13 | $3,112 | $239 |
| Diovan | 12 | $2,209 | $184 |
| Paroxetine | 11 | $891 | $81 |
| Isosorbide Dinitrate | 12 | $319 | $27 |
| Tramadol | 49 | $245 | $5 |
| Azithromycin | 28 | $240 | $9 |
| Amlodipine Besylate | 37 | $184 | $5 |
| Levothyroxine | 17 | $180 | $11 |
| Ibuprofen | 21 | $167 | $8 |
| Ciprofloxacin | 26 | $156 | $6 |
| Armour Thyroid | 19 | $148 | $8 |
| Cephalexin | 24 | $139 | $6 |
| Hydrocodone-Acetaminophen | 14 | $131 | $9 |
| Buspirone | 11 | $127 | $12 |
| Lisinopril | 14 | $119 | $9 |
| Simvastatin | 13 | $94 | $7 |
| Omeprazole | 14 | $82 | $6 |
| Sulfamethoxazole-Trimethoprim | 13 | $77 | $6 |
| Amoxicillin | 13 | $66 | $5 |
| Temazepam | 16 | $56 | $3 |
Money from drug and device companies
$157 in 2023
| 2023 | 2 | 4 | None | $157 |
| 2019 | 2 | 2 | None | $76 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Shingrix | $134 | 3 payments
|
| Exact Sciences | Cologuard Collection Kit | $24 | 1 payment
|
See all 4 published payments
| Exact Sciences | Meals · 2023-12-12 | Cologuard Collection Kit | $24 |
| GlaxoSmithKline | Meals · 2023-07-12 | Arexvy | $23 |
| GlaxoSmithKline | Meals · 2023-01-25 | Shingrix | $19 |
| GlaxoSmithKline | Meals · 2023-01-25 | Shingrix | $91 |
See earlier years (2019)
2019: $76
| Scilex Pharmaceuticals | Ztlido 30 Pouch in 1 Carton 1 Patch in 1 Pouch | $61 | 1 payment
|
| Emergent BioSolutions | Narcan | $15 | 1 payment
|
Professional record
- NPI
- 1689014755
- Licence
- CA A125643California A125643: Current · expires 2027-03-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 625 Lincoln Ave, San Jose, CA, 95126
- NPI first listed
- 2013-07-03
- NPI last updated
- 2020-11-11
- NPI record certified
- 2020-11-11
This is when the NPI record was last certified, not a medical board exam.